Velocity Pharmaceutical Development

Velocity Pharmaceutical Development (VPD) was established in 2011 by Presidio Partners as an alternative model to develop attractive drug candidates that would otherwise be funded as part of a broader company financing or not be funded due to strategic reasons or resource limitations. The company’s founders, David Collier, Ed Schnipper, Jim Larrick and Andy Perlman, recognized that many high potential drug candidates are underfunded or shelved due to the inherent inefficiencies in traditional drug development within small and large biotech and pharmaceutical companies. Their solution was to invest in drug candidates and not companies. This was the inspiration for the Velocity model that establishes a project focused company (PFC) to house drug candidates acquired from third parties. By partnering with VPD, the owner of a drug candidate can achieve the funding needed to take the drug candidate to clinical proof-of-concept while accessing a world-class team to design and manage the development program. The contributor of the drug candidate receives equity in the new PFC created to house its drug program and benefits from the ultimate financial upside upon clinical success and sale of the PFC to a pharmaceutical company.

Vitesse Biologics

Baxalta Ventures, Mayo Clinic and Velocity Pharmaceutical Development formed Vitesse Biologics in June 2015 to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology.


Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing transformative therapies to treat orphan and underserved disease conditions in hematology, immunology and oncology. Baxalta spun-off from Baxter International Inc. on July 1, 2015.
Purpose-Driven Performance
Baxalta has a solid foundation and our patient-focused strategy, disciplined financial management, transformative culture and people, position us well to drive profitable growth and enhance value for patients, customers and shareholders.

$6bn revenue 2014
6-8% ↑ revenue expected through 2020
$500mm expected size of oncology franchise by 2020
$2.5bn expected revenue from new product launches by 2020
12 high quality manufacturing sites in 7 countries

Our Pipeline
Our targeted innovation strategy and cutting-edge science, combined with strategic partnerships, come together to spark discovery and deliver innovation for patients with limited treatment options.

3 global businesses: hematology, immunology, oncology
40+ programs in the pipeline
12 new molecular entities
$595mm R&D investment in 2014
20 product launches expected in next 5 years

The Panorama Institute of Molecular Medicine

The Panorama Institute of Molecular Medicine is a leader in the development of new therapeutics based on fundamental scientific discoveries. As a non-profit biomedical research facility, we conduct basic and applied research that will lead to medical advances to treat a wide range of diseases from cancer to heart failure. The Panorama Institute of Molecular Medicine is partnered with Panorama Research Inc.